Global Statistics

All countries
546,947,158
Confirmed
Updated on June 23, 2022 4:17 pm
All countries
519,314,523
Recovered
Updated on June 23, 2022 4:17 pm
All countries
6,346,310
Deaths
Updated on June 23, 2022 4:17 pm

Global Statistics

All countries
546,947,158
Confirmed
Updated on June 23, 2022 4:17 pm
All countries
519,314,523
Recovered
Updated on June 23, 2022 4:17 pm
All countries
6,346,310
Deaths
Updated on June 23, 2022 4:17 pm
- Advertisment -

Is The Covid Vaccine Effective

New Covid Vaccine Highly Effective Against Severe Disease Companies Say

WATCH: Which COVID vaccine is most effective?

The companies, Sanofi and GSK, say they plan to submit data to the FDA and regulators in Europe.

Jessica Rendall

Jessica is a Wellness News Writer who wants to help people stay informed about their health. She’s from the Midwest, studied investigative reporting at the Missouri School of Journalism and is now based in NYC.

A new COVID vaccine was 100% effective at preventing COVID-19 hospitalization during a clinical trial, the vaccine’s makers, Sanofi and GSK, said Wednesday in a press release. As promising data rolls in, the companies plan to seek authorization from the US Food and Drug Administration and regulators in Europe.

The two-dose vaccine was also 75% effective at preventing “moderate or severe” COVID-19 disease in Phase 3 of the trial, as well as 57.9% effective against symptomatic disease. This is in line, the companies said, with expected vaccine effectiveness during a time when variants of concern were dominant.

The vaccine is also effective as a booster for people who’ve been vaccinated with another COVID-19 vaccine, the companies said. They will also ask the FDA and other regulators to consider it as a booster candidate.

Our Health & Wellness newsletter puts the best products, updates and advice in your inbox.

, a similar vaccine, submitted data for authorization to the FDA last month.

Read more: Here’s How Long Your COVID Vaccine Booster Provides Protection

Q: Why Did The Fda And Cdc Make The Decision To Resume The Use Of The Janssen Covid

A: On April 23, 2021, the FDA and CDC lifted the recommended pause on the Janssen COVID-19 Vaccine after a thorough evaluation of the available safety data pertaining to thrombosis with thrombocytopenia syndrome . The data, plus the deliberations and recommendations of CDCs Advisory Committee on Immunization Practices , helped with our assessment that the known and potential benefits of Janssen COVID-19 Vaccine outweigh its known and potential risks in individuals 18 years of age and older. At the time, the available data suggested the chance of this serious adverse event occurring was remote, but investigation into the level of potential excess risk due to vaccination and specific risk factors continued.

We informed the public of these cases and noted that a causal relationship with Janssen COVID-19 Vaccine is plausible for TTS. The FDA and CDC continues to fully investigate all reports of TTS and to closely monitor the safety of all COVID-19 vaccines.

Here When You Need Us

We are expanding to ensure that were right where you need us. We currently offer more than 220 specialized clinical services in close to 200 locations throughout Connecticut, New York and Rhode Island. And we offer telehealth too, making our specialty care easily available no matter where you live.

Whatever your needs, wherever you are, know that our doctors work as a team to provide the care you need. We take the time to listen. We know that you are the most important member of your health care team we develop care plans with you, instead of for you. Our collaborative approach ensures you receive the care you need, before, during and after each visit.

Recommended Reading: How Much Is Pcr Test At Cvs

How Effective Is The Covid

As with any vaccine, the Pfizer vaccine may not fully protect everyone who gets it. However, it is highly effective if people have both doses. That means, if you do catch COVID-19, youre far less likely to fall seriously ill and less likely to transmit the virus to others.

The COVID-19 vaccine stimulates your bodys immune system to produce antibodies and other proteins that will fight the virus if youre exposed to it. This reduces the risk of getting infected and if you do get COVID-19, it means you could have no symptoms or will have much fewer, milder symptoms and recover faster.

While the data is clear that vaccines protect people from the effects of COVID-19, research is ongoing to determine whether a vaccinated person could still transmit the virus to someone else so to be safe, we must assume there is still a risk of transmission.

English

The point of the vaccine is it dramatically reduces your risk of getting COVID-19, absolutely.

If you have been vaccinated, even with the Delta variant youve got more than 90% chance of not ending up in hospital, not being in intensive care and not dying. So thats pretty bloody good odds.

How Are We Monitoring The Coronavirus Vaccines

VACCINE COMING SOON  Pfizer

Pfizer and Moderna have been monitoring immunity in people who were given their vaccines in the initial clinical trialsboth companies had reported strong overall efficacy at the six-month mark.

One thing researchers are monitoring in vaccine recipients is levels of antibodies, which are proteins produced by the bodys immune system when it detects harmful substances, and that are easily measured from blood samples. Antibodies are a really good marker for protection against infection, so we will be monitoring those levels for as long as we can measure them, says Akiko Iwasaki, PhD, a professor of immunobiology at Yale School of Medicine.

I tell my family, ‘It’s great that youre vaccinated… But even the vaccines dont have 100% guarantees, so… you want to keep weighing the risks,'” says Yale Medicine infectious diseases expert Jaimie Meyer, MD, MS

A report in The New England Journal of Medicine in April showed that 33 participants who had received the Moderna vaccine during the Phase I trial had a gradual decline in antibody protectionand, based on the slope, Iwasaki says, that is hopeful news. If antibodies are going down very quickly, you would expect that to last for a short time. The slow decline raises hopes that the mRNA vaccines will be protective for at least a year, if not longer, she says.

This is a reason why the CDC recommends vaccinations for people who have had a COVID-19 infection as well as for those who have not.

You May Like: Covid Test Cost Cvs

J& j Vaccine Effectively Helps Protect Against Hospitalization And Death From Covid

So far, over 14 million people in the U.S. have received the J& J vaccine. But ever since it was authorized, the J& J vaccine has experienced some media challenges. The vaccines reported effectiveness has differed from that of the mRNA vaccines, and its use was temporarily paused earlier this year due to concerns over rare blood clots.

In initial clinical trials, the vaccine was about 66% effective at preventing COVID-19 infections. This drew some media attention at face value it seemed less effective than the other vaccines. But the vaccine was studied under different conditions.

Fast forward to today, and more data is available that speaks to its effectiveness. In early July, data from two studies showed that one dose of the vaccine provides immune protection that lasts for at least 8 months. These studies have not yet been published, but they were reported by Johnson & Johnson.

Also, in early August, a large South African study referred to as the Sisonke study showed that the vaccine was about 95% effective against death and 71% effective against hospitalization due to the Delta variant in healthcare workers.

  • What this means: The J& J vaccine, like the mRNA vaccines, is considered effective against the COVID-19 Delta variant.

  • What this doesnt mean: The J& J vaccine should be preferred over the other vaccines.

To read more about this data, click or tap here.

Phase Two And Three Clinical Trials Vaccine And Placebo

The efficacy of the Pfizer vaccine was tested in about 44,000 participants aged 16 years and over where COVID-19 was already circulating in communities. About half of these participants were randomised to receive the vaccine and the other half received a saline placebo.

The trial looked at how many people got COVID-19 symptoms after they were vaccinated compared to how many got COVID-19 after getting the placebo.

Participants had two doses of the vaccine or placebo, getting their second dose within 19 to 42 days after their first dose. They were then closely monitored and evaluated for at least 2 months after their second dose.

Recommended Reading: Cvs Pcr Test For Travel Price

Pfizer Moderna Fared Better Than J& j

An observational study led by University of North Carolina at Chapel Hill researchers involved mining data on COVID-related outcomes and vaccination with the Pfizer, Moderna, and Johnson & Johnson vaccines from Dec 11, 2020, to Sep 8, 2021, for about 10.6 million state residents.

Two months after receipt of the first Pfizer or Moderna COVID-19 vaccine dose, estimated VE against symptomatic or asymptomatic infection was 94.5% and 95.9% , respectively, declining to 66.6% and 80.3% , respectively, by 7 months.

Estimated VE among patients who received the Pfizer or Moderna vaccine early fell by roughly 15 and 10 percentage points, respectively, from mid-June to mid-July, when the Delta variant became dominant.

Among recipients of the one-dose J& J vaccine, VE against infection was 74.8% at 1 month, dropping to 59.4% at 5 months.

VE against hospitalization or death after two doses of the Pfizer vaccine peaked at 96.4% at 2 months and was still at 88.7% at 7 months. Moderna two-dose effectiveness peaked at 97.2% at 2 months and was still 94.1% at 7 months. VE of the J& J vaccine peaked at 85.8% at 2 months and remained higher than 80% through 6 months.

All three vaccines were better at preventing hospitalization and death over time than at preventing infection, although the Pfizer and Moderna vaccines offered more protection than J& J.

What Share Of The Population Has Been Partly Or Fully Vaccinated Against Covid

Which Covid-19 vaccine is most effective?

The following charts show the breakdown of vaccinations by those that have been partly or fully vaccinated. A person is considered partly vaccinated if they have received only one dose of a 2-dose vaccine protocol. A person is considered fully vaccinated if they have received a single-dose vaccine or both doses of a two-dose vaccine.

This data is only available for countries which report the breakdown of doses administered by first and second doses.

Also Check: How Much Does A Rapid Test Cost At Cvs

What About The Blood Clot Issue

A number of AstraZeneca recipients in Europe have reported blood clots after getting the jab, casting doubt on its safety. But a European Union medicine regulator said Tuesday there was “no indication” that AstraZeneca’s vaccines are causing the reported clots.

Dr. Lynora Saxinger, an infectious disease specialist with the University of Alberta, says a blood clot, or a pulmonary embolism, is “an incredibly common thing.”

Saxinger said she would need to see more information about the blood clots that are being reported, such as how old the recipients are. But numbers of those reporting the clots should also be seen in the context of how many people get the vaccine and don’t report that side effect, she added.

“We did not see any signal of in the trials of the vaccine, which had tens of thousands of people in them,” Saxinger said.

Chagla says data suggests the number of those reporting blood clots is well within the normal range experts would expect to see in a given population, meaning they may have happened in those people whether they got the vaccine or not.

AstraZeneca said over the weekend that a review of 17 million patients who received the shot in Europe and the U.K. shows no elevated risk of blood clotting.

Q: Is It Possible To Make Comparisons About The Effectiveness Among The Three Covid

A: No. The only way to accurately compare the effectiveness of medical products, such as vaccines or drugs, is by direct comparison in head-to-head clinical trials, which did not occur for these vaccines. Furthermore, the clinical trials for these vaccines occurred in different geographic regions and at different points in time with varying incidence of COVID-19. All of the COVID-19 vaccines the FDA has authorized for emergency use are at least 50% more effective than placebo in preventing COVID-19, consistent with FDA recommendations provided in our October 2020 guidance document, Emergency Use Authorization for Vaccines to Prevent COVID-19. A vaccine with at least 50% efficacy would have a significant impact on disease, both at the individual and societal level.

Read Also: Cost Of Cvs Covid Test

Vaccine Protection And Infection

Vaccines can stop most people from getting sick with COVID-19, but not everyone.

Even after someone takes all of the recommended doses and waits a few weeks for immunity to build up, there is still a chance that they can get infected. Vaccines do not provide full protection, so breakthrough infections where people get the virus, despite having been fully vaccinated will occur.

If vaccinated people do get sick, they are likely to have milder symptoms, in general ‘It is very rare for someone vaccinated to experience severe illness or die.

Omicron Vs Delta: Vaccines Seem Less Effective

Moderna says new data shows its Covid vaccine is more than ...

Early estimates suggest that vaccine effectiveness against symptomatic infection with Omicron is significantly lower compared with the Delta variant.

A report by Imperial College London indicated that the risk of reinfection with Omicron was 5.4 times greater than the Delta variant. Previously having COVID-19 also afforded little protection against reinfection with Omicron.

This is such a contagious virus that it can spread not only among the unvaccinated, where I think it still has a very substantial risk of causing serious disease that might require hospitalization, but it can also spread among vaccinated persons, although the illness it produces among the vaccinated, particularly if youve had a boost, is generally mild and even without symptoms, said Dr. William Schaffner, a professor of preventive medicine and infectious diseases at Vanderbilt University Medical Center in Tennessee.

However, the Imperial College London study suggests that there is no evidence of Omicron having different severity from Delta, despite hospitalization remaining relatively low for the time being.

Omicron may not lead to more severe illness than Delta, a rapid and massive surge in infections could still overwhelm hospitals with sick patients. People who are unvaccinated remain at the highest risk, but also those who have not received a third dose of an mRNA vaccine, said Dr. Robert Glatter, an emergency physician at Lenox Hill Hospital in New York City.

Read Also: How Much Is The Pcr Test At Cvs

Q: Who May Receive A Booster Dose Of The Janssen Covid

A: A single booster dose may be administered at least 2 months after completion of primary vaccination with the Janssen COVID-19 Vaccine in individuals 18 years of age and older. A single booster dose may be administered to individuals 18 years of age and older as a heterologous booster dose following completion of primary vaccination with a different authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.

Vaccine Protection And Timing

Vaccines offer strong protection, but that protection takes time to build. People must take all the required doses of a vaccine to build full immunity. For two-dose vaccines, vaccines only give partial protection after the first dose, and the second dose increases that protection. It takes time before protection reaches its maximum level a few weeks after the second dose. For a one-dose vaccine, people will have built maximum immunity against COVID-19 a few weeks after getting vaccinated.

You May Like: How Long Does The Cvs Rapid Test Take

Q: Why Did The Fda And Cdc Recommend A Pause In The Use Of The Janssen Covid

A: As a result of ongoing safety monitoring, on April 13, 2021, the FDA and CDC recommended a temporary pause in the use of Janssen COVID-19 Vaccine, due to reports of a serious and rare type of blood clot in combination with low blood platelets . This serious condition is called thrombosis with thrombocytopenia syndrome .

Out of an abundance of caution, the FDA and CDC recommended a pause in the use of the Janssen COVID-19 Vaccine while the FDA and CDC investigated these reports of serious adverse events. This was important, in part, to help ensure that health care providers were made aware of the potential for these adverse events and could plan for proper recognition and management due to the unique treatment required for TTS.

The safety monitoring program that is in place to monitor COVID-19 vaccines is working, as we were able to detect the reports of these serious adverse events early and take action to assess them.

Laboratory Study Suggests That Three Pfizer Shots Neutralizes The New Variant

Russia: Sputnik vaccine is 92% effective against coronavirus

In late November, the World Health Organization announced the Omicron variant is a variant of concern. Today, Pfizer announced preliminary findings from a laboratory study testing their COVID-19 vaccine against this new variant.

The initial findings suggest that three doses of their vaccine helps create enough antibodies to neutralize the Omicron variant. This is thought to lead to protection thats similar to two doses that have been effective against other variants.

In the same press release, Pfizer said that two doses of their vaccine may still protect against severe COVID-19. But compared to previous variants, two doses may provide less protection against new infections.

But, importantly, these results are from an early laboratory study. Since the Omicron variant was only recently identified, there hasnt been enough time to directly study the vaccines effectiveness in people. More effectiveness data will likely be announced as more becomes known about this variant.

  • What this means: A Pfizer booster shot may help protect against illness caused by the Omicron variant. Aside from these findings, booster shots are currently recommended for all adults based on when their initial vaccine series was completed.

  • Keep in mind: This information is not widely generalizable. These are early laboratory findings that look at the difference in antibodies from two or three shots against the Omicron variant.

To read more about this update, click or tap here.

Don’t Miss: How Long Does Rapid Testing Take At Cvs

- Advertisment -

Hot Topics

- Advertisment -

Related Articles